Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free PYC Stock Alerts

Physiomics (PYC) Competitors

Physiomics logo
GBX 0.62 +0.02 (+3.99%)
As of 06/8/2026 11:18 AM Eastern
Compare

PYC vs. CIZ, GENF, SNG, BVX, and OBD

Should you buy Physiomics stock or one of its competitors? MarketBeat compares Physiomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Physiomics include Cizzle Biotechnology (CIZ), Genflow Biosciences (GENF), Synairgen (SNG), BiVictriX Therapeutics (BVX), and Oxford BioDynamics (OBD). These companies are all part of the "biotechnology" industry.

How does Physiomics compare to Cizzle Biotechnology?

Cizzle Biotechnology (LON:CIZ) and Physiomics (LON:PYC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Cizzle Biotechnology has a net margin of 0.00% compared to Physiomics' net margin of -50.92%. Cizzle Biotechnology's return on equity of 104.99% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cizzle BiotechnologyN/A 104.99% -31.72%
Physiomics -50.92%-89.43%-76.38%

0.0% of Cizzle Biotechnology shares are held by institutional investors. Comparatively, 0.8% of Physiomics shares are held by institutional investors. 65.9% of Cizzle Biotechnology shares are held by insiders. Comparatively, 3.3% of Physiomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cizzle Biotechnology has a beta of 0.068073176, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Physiomics has a beta of 0.946, indicating that its stock price is 5% less volatile than the broader market.

Cizzle Biotechnology has higher earnings, but lower revenue than Physiomics. Cizzle Biotechnology is trading at a lower price-to-earnings ratio than Physiomics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cizzle BiotechnologyN/AN/A-£2.81K-£0.17N/A
Physiomics£953.01K2.97-£922.82K-£0.15N/A

In the previous week, Cizzle Biotechnology had 1 more articles in the media than Physiomics. MarketBeat recorded 1 mentions for Cizzle Biotechnology and 0 mentions for Physiomics. Cizzle Biotechnology's average media sentiment score of 0.00 equaled Physiomics'average media sentiment score.

Company Overall Sentiment
Cizzle Biotechnology Neutral
Physiomics Neutral

Summary

Cizzle Biotechnology beats Physiomics on 6 of the 11 factors compared between the two stocks.

How does Physiomics compare to Genflow Biosciences?

Genflow Biosciences (LON:GENF) and Physiomics (LON:PYC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 0.8% of Physiomics shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by insiders. Comparatively, 3.3% of Physiomics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Physiomics has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than Physiomics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Physiomics£953.01K2.97-£922.82K-£0.15N/A

In the previous week, Genflow Biosciences had 1 more articles in the media than Physiomics. MarketBeat recorded 1 mentions for Genflow Biosciences and 0 mentions for Physiomics. Genflow Biosciences' average media sentiment score of 0.00 equaled Physiomics'average media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Physiomics Neutral

Genflow Biosciences has a beta of 2.108, meaning that its share price is 111% more volatile than the broader market. Comparatively, Physiomics has a beta of 0.946, meaning that its share price is 5% less volatile than the broader market.

Genflow Biosciences has a net margin of 840.76% compared to Physiomics' net margin of -50.92%. Genflow Biosciences' return on equity of 377.33% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences840.76% 377.33% -58.66%
Physiomics -50.92%-89.43%-76.38%

Summary

Genflow Biosciences beats Physiomics on 6 of the 11 factors compared between the two stocks.

How does Physiomics compare to Synairgen?

Synairgen (LON:SNG) and Physiomics (LON:PYC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Synairgen has a net margin of 0.00% compared to Physiomics' net margin of -50.92%. Synairgen's return on equity of -51.06% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
SynairgenN/A -51.06% -30.58%
Physiomics -50.92%-89.43%-76.38%

Synairgen has a beta of -2.23, indicating that its stock price is 323% less volatile than the broader market. Comparatively, Physiomics has a beta of 0.946, indicating that its stock price is 5% less volatile than the broader market.

In the previous week, Synairgen's average media sentiment score of 0.00 equaled Physiomics'average media sentiment score.

Company Overall Sentiment
Synairgen Neutral
Physiomics Neutral

Physiomics has higher revenue and earnings than Synairgen. Physiomics is trading at a lower price-to-earnings ratio than Synairgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SynairgenN/AN/A-£15.86M-£1.66N/A
Physiomics£953.01K2.97-£922.82K-£0.15N/A

30.7% of Synairgen shares are held by institutional investors. Comparatively, 0.8% of Physiomics shares are held by institutional investors. 3.2% of Synairgen shares are held by insiders. Comparatively, 3.3% of Physiomics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Synairgen and Physiomics tied by winning 5 of the 10 factors compared between the two stocks.

How does Physiomics compare to BiVictriX Therapeutics?

Physiomics (LON:PYC) and BiVictriX Therapeutics (LON:BVX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Physiomics' average media sentiment score of 0.00 equaled BiVictriX Therapeutics'average media sentiment score.

Company Overall Sentiment
Physiomics Neutral
BiVictriX Therapeutics Neutral

Physiomics has a beta of 0.946, meaning that its share price is 5% less volatile than the broader market. Comparatively, BiVictriX Therapeutics has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market.

Physiomics has higher revenue and earnings than BiVictriX Therapeutics. Physiomics is trading at a lower price-to-earnings ratio than BiVictriX Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Physiomics£953.01K2.97-£922.82K-£0.15N/A
BiVictriX TherapeuticsN/AN/A-£2.67M-£0.04N/A

BiVictriX Therapeutics has a net margin of 0.00% compared to Physiomics' net margin of -50.92%. Physiomics' return on equity of -89.43% beat BiVictriX Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Physiomics-50.92% -89.43% -76.38%
BiVictriX Therapeutics N/A -103.99%-62.99%

0.8% of Physiomics shares are owned by institutional investors. Comparatively, 30.8% of BiVictriX Therapeutics shares are owned by institutional investors. 3.3% of Physiomics shares are owned by company insiders. Comparatively, 42.6% of BiVictriX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Physiomics and BiVictriX Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Physiomics compare to Oxford BioDynamics?

Physiomics (LON:PYC) and Oxford BioDynamics (LON:OBD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

Physiomics has higher earnings, but lower revenue than Oxford BioDynamics. Physiomics is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Physiomics£953.01K2.97-£922.82K-£0.15N/A
Oxford BioDynamics£1.10M7.33-£103.52M-£0.80N/A

Physiomics has a beta of 0.946, indicating that its share price is 5% less volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Physiomics has a net margin of -50.92% compared to Oxford BioDynamics' net margin of -1,018.54%. Physiomics' return on equity of -89.43% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Physiomics-50.92% -89.43% -76.38%
Oxford BioDynamics -1,018.54%-316.67%-56.23%

0.8% of Physiomics shares are held by institutional investors. Comparatively, 25.4% of Oxford BioDynamics shares are held by institutional investors. 3.3% of Physiomics shares are held by insiders. Comparatively, 15.6% of Oxford BioDynamics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Physiomics' average media sentiment score of 0.00 equaled Oxford BioDynamics'average media sentiment score.

Company Overall Sentiment
Physiomics Neutral
Oxford BioDynamics Neutral

Summary

Oxford BioDynamics beats Physiomics on 6 of the 11 factors compared between the two stocks.

Get Physiomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PYC vs. The Competition

Export
MetricPhysiomicsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£2.83M£435.53M£6.49B£2.75B
Dividend Yield6.20%3.86%2.67%6.16%
P/E Ratio-4.173.2023.68366.44
Price / Sales2.976,458.64507.3387,084.52
Price / Cash4.2113.1326.9927.85
Price / Book3.0083.7910.287.61
Net Income-£922.82K-£96.07M£3.57B£5.89B
7 Day Performance-10.71%-1.41%0.28%-1.07%
1 Month Performance13.64%0.92%3.27%1.57%
1 Year Performance36.17%53.98%22.22%72.07%

Physiomics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PYC
Physiomics
N/AGBX 0.63
+4.0%		N/A+35.9%£2.83M£953.01KN/A10
CIZ
Cizzle Biotechnology
N/AGBX 2.95
+3.1%		N/A+45.5%£11.69MN/AN/A4
GENF
Genflow Biosciences
N/AGBX 2.13
+1.2%		N/A+148.2%£11.38MN/AN/A5
SNG
Synairgen
N/AN/AN/AN/A£9.04MN/AN/A34
BVX
BiVictriX Therapeutics
N/AN/AN/AN/A£8.25MN/AN/A17

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:PYC) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel